Personalis

PSNL

Market cap $1.13B

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) today announced clinical data from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting establishing the clinical importance of ultrasensitive MRD detection across six solid tumor types, led by the VICTORI colorectal cancer and TRACERx lung cancer studies. “Our ASCO data continues to build on a compelling body of evidence, including recent landmark publications, that show ultrasensitive MRD detection with NeXT Per.

Personalis, Inc. is rated Buy, driven by strong momentum in its NeXT Personal Dx MRD test and recent Medicare coverage expansions. Despite a projected 2026 net loss of ~$100m and 14% revenue growth, PSNL's clinical test volume is ramping rapidly, with 43k–45k tests targeted this year. Key catalysts include expanded CMS MolDX coverage for breast and lung cancer recurrence monitoring and potential M&A interest given an $887m market cap.

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that six clinical abstracts demonstrating the broad use of its NeXT Personal® test will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 to June 2 in Chicago. Highlights include an oral podium presentation from the landmark TRACERx study, which demonstrates the clinical impact of NeXT Personal's single-d.

Personalis Inc. (NASDAQ:PSNL) received a favorable reimbursement decision that could make its cancer test available to more patients — and more likely to be paid for by Medicare.

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) has expanded coverage for the company's NeXT Personal minimal residual disease (MRD) test. The new coverage determination is for monitoring treatment response to neoadjuvant therapy (NAT) in patients diagnosed with Stage II-III Triple-Negative Breast Canc.

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be participating in the following investor events: Craig Hallum 23rd Annual Institutional Investor Conference on May 28, 2026 at the Depot Renaissance Hotel in Minneapolis, MN. Jefferies 2026 Global Healthcare Conference on June 3, 2026 at the Marriot Marquis in New York, NY. About Personalis, Inc. At Personalis, we are transformi.

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) has expanded coverage for the company's NeXT Personal minimal residual disease (MRD) test to include immunotherapy monitoring for patients with late-stage solid tumors. This coverage determination is underpinned by landmark clinical evidence generated in.

Personalis NASDAQ: PSNL reported first-quarter 2026 revenue of $15.5 million as management said the company is prioritizing growth in its clinical minimal residual disease, or MRD, testing business and biopharma MRD programs over lower-margin legacy enterprise revenue.

Personalis, Inc. (PSNL) Q1 2026 Earnings Call Transcript

Personalis (PSNL) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.18 per share a year ago.